

ROBERT K. STOELTING

---

PHARMACOLOGY  
and PHYSIOLOGY  
in ANESTHETIC  
PRACTICE

---

# PHARMACOLOGY AND PHYSIOLOGY IN ANESTHETIC PRACTICE

---

ROBERT K. STOELTING, M.D.

Professor and Chairman  
Department of Anesthesia  
Indiana University School of Medicine  
Indianapolis, Indiana



J. B. LIPPINCOTT COMPANY

Philadelphia

London    Mexico City    New York    St. Louis    São Paulo    Sydney

Acquisitions Editor: Lewis Reines  
Sponsoring Editor: Sanford J. Robinson  
Manuscript Editor: Helen Ewan  
Indexer: Barbara Littlewood  
Art Director: Tracy Baldwin  
Production Manager: Kathleen P. Dunn  
Production Coordinator: George V. Gordon  
Compositor: Progressive Typographers  
Printer/Binder: R. R. Donnelley & Sons Company

Copyright © 1987, by J. B. Lippincott Company.  
All rights reserved.

No part of this book may be used or reproduced in any manner whatsoever without written permission except for brief quotations embodied in critical articles and reviews. Printed in the United States of America. For information write J. B. Lippincott Company, East Washington Square, Philadelphia, Pennsylvania 19105.

6

#### Library of Congress Cataloging-in-Publication Data

Stoelting, Robert K.

Pharmacology and physiology in anesthetic practice.

Includes bibliographies and indexes.

1. Anesthetics — Physiological effect. 2. Anesthesia.

3. Human physiology. 4. Pharmacology. I. Title.

[DNLM: 1. Anesthetics — pharmacodynamics. 2. Physiology.

QV 81 S872p]

RD81.S87 1987 615'.781 86-21017

ISBN 0-397-50771-2

The author and publisher have ~~exerted every effort~~ <sup>made every effort</sup> to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

---

# P R E F A C E

---

Anesthesiology is a medical specialty that requires daily application of principles of pharmacology and physiology in the care of patients. Reference textbooks of pharmacology and physiology often serve as the repository of information that is pertinent to all medical aspects of pharmacology and physiology. Clearly, only portions of these textbooks are relevant to the clinical practice of anesthesia. In this regard, the goal of *Pharmacology and Physiology in Anesthetic Practice* is to provide students as well as practicing anesthesiologists with an in-depth but concise and current presentation of those aspects of pharmacology and physiology that are relevant either directly or indirectly to the perioperative anesthetic management of patients.

Preparation of a textbook of this scope requires unique and reliable support from others. In this regard, special accolades go to my secretary, Deanna Walker, for her skillful preparation of the many revisions that preceded the final manuscript. Ellyn Traub receives my appreciation for her skillful preparation of the original art work. Lewis Reines, president of J. B. Lippincott Company, again earned my admiration for his professionalism and constant ability to provide encouragement and resources for the evolution of this textbook. Finally, my wife and daughters deserve my special thanks for again enduring the time commitment required for another textbook.

Robert K. Stoelting, M.D.

---

# C O N T E N T S

---

## SECTION I

### PHARMACOLOGY

- 1  
Pharmacokinetics and Pharmacodynamics of  
Injected and Inhaled Drugs 2  
    Introduction 2  
    Description of Drug Response 2  
    Pharmacokinetics of Injected Drugs 3  
    Pharmacodynamics of Injected Drugs 18  
    Pharmacokinetics of Inhaled Anesthetics 21  
    Pharmacodynamics of Inhaled  
        Anesthetics 30
- 2  
Inhaled Anesthetics 35  
    Introduction 35  
    Comparative Pharmacology 38  
    Central Nervous System Effects 38  
    Circulatory Effects 41  
    Ventilation Effects 49  
    Hepatic Effects 53  
    Renal Effects 55  
    Skeletal Muscle Effects 56  
    Obstetric Effects 57  
    Resistance to Infection 58  
    Genetic Effects 58  
    Bone Marrow Effects 59  
    Peripheral Neuropathy 59  
    Total Body Oxygen Requirements 59
- 3  
Opioid Agonists and Antagonists 69  
    Introduction 69  
    Structure Activity Relationships 69  
    Mechanism of Action 70  
    Opioid Receptors 71  
    Opioid Agonists 73  
    Opioid Agonist-Antagonists 90  
    Opioid Antagonists 94  
    Anesthetic Requirements 95
- 4  
Barbiturates 102  
    Introduction 102  
    Commercial Preparations 102  
    Structure Activity Relationships 102  
    Mechanism of Action 103  
    Pharmacokinetics 104  
    Clinical Uses 108  
    Side Effects 110
- 5  
Benzodiazepines 117  
    Introduction 117  
    Structure Activity Relationships 117  
    Mechanism of Action 117  
    Diazepam 119  
    Midazolam 125  
    Lorazepam 129

Oxazepam	129	Overdose of Anticholinesterase Drugs	228
Chlordiazepoxide	130	Synthetic Cholinergic Agonists	229
Clonazepam	130		
Flurazepam	130	10	
Temazepam	130	Anticholinergic Drugs	232
Triazolam	130	Introduction	232
Clorazepate	130	Structure Activity Relationships	232
Halazepam	130	Mechanism of Action	232
Prazepam	131	Pharmacokinetics	233
		Clinical Uses	234
6		Central Anticholinergic Syndrome	238
Nonbarbiturate Induction Drugs	134	Overdose	238
Ketamine	134		
Etomidate	141	11	
Propofol	143	Nonopioid and Nonsteroidal Analgesic,	
Alphadione	144	Antipyretic, and Anti-inflammatory Drugs	240
Propanidid	144	Introduction	240
		Mechanism of Action	240
7		Salicylates	241
Local Anesthetics	148	Phenylbutazone	243
Introduction	148	Para-aminophenol Derivatives	244
Commercial Preparations	148	Indomethacin	245
Structure Activity Relationships	149	Propionic Acid Derivatives	245
Pharmacokinetics	150	Tolmetin	246
Mechanism of Action	156	Zomepirac	246
Minimum Concentration	157	Diffunisal	247
Side Effects	158	Gold	247
Uses of Local Anesthetics	161	Colchicine	247
		Allopurinol	248
8		Uricosuric Drugs	248
Neuromuscular Blocking Drugs	169		
Introduction	169	12	
History	169	Sympathomimetics	251
Clinical Uses	170	Introduction	251
Structure Activity Relationships	170	Clinical Uses	251
Neuromuscular Junction	172	Structure Activity Relationships	253
Depolarizing Neuromuscular Blocking		Mechanism of Action	254
Drugs	174	Metabolism	256
Long-Acting Nondepolarizing		Route of Administration	257
Neuromuscular Blocking Drugs	180	Naturally Occurring Catecholamines	257
Intermediate-Acting Nondepolarizing		Synthetic Catecholamines	261
Neuromuscular Blocking Drugs	198	Synthetic Noncatecholamines	262
		Selective Beta-2 Agonists	265
9			
Anticholinesterase Drugs and Cholinergic		13	
Agonists	217	Digitalis and Related Drugs	269
Classification	217	Introduction	269
Structure Activity Relationships	219	Clinical Uses	269
Pharmacokinetics	219	Structure Activity Relationships	269
Pharmacologic Effects	222	Mechanism of Action	270
Clinical Uses	223	Pharmacokinetics	271

Cardiovascular Effects	273	Pharmacologic Effects	335
Electrocardiographic Effects	273	Clinical Uses	336
Digitalis Toxicity	274	Drug Interactions	338
Preoperative Prophylactic Digitalis	275	Verapamil	342
Drug Interactions	276	Nifedipine	344
Noncatecholamine Nonglycoside Cardiac Inotropes	276	Diltiazem	344
<b>14</b>		<b>19</b>	
<b>Alpha- and Beta-adrenergic Receptor Antagonists</b>	280	<b>Drugs Used in Treatment of Psychiatric Disease</b>	347
Introduction	280	Introduction	347
Alpha-adrenergic Receptor Antagonists	280	Phenothiazines and Thioxanthenes	347
Beta-adrenergic Receptor Antagonists	282	Butyrophenones	350
<b>15</b>		Lithium	353
<b>Antihypertensive Drugs</b>	294	Tricyclic Antidepressants	355
Introduction	294	Monoamine Oxidase Inhibitors	359
Methyldopa	294	Disulfiram	362
Clonidine	297	<b>20</b>	
Reserpine	298	<b>Prostaglandins</b>	365
Guanabenz	299	Introduction	365
Hydralazine	299	Nomenclature and Structure Activity Relationships	365
Prazosin	300	Synthesis	365
Minoxidil	301	Mechanism of Action	366
Guanethidine	301	Metabolism	366
Guanadrel	302	Effects on Organ Systems	367
Labetalol	302	<b>21</b>	
Captopril	303	<b>Histamine and Histamine Receptor Antagonists</b>	373
Saralasin	304	Histamine	373
Metirosine	304	Histamine Receptor Antagonists	375
<b>16</b>		Cromolyn	382
<b>Peripheral Vasodilators</b>	307	<b>22</b>	
Introduction	307	<b>Renin, Plasma Kinins, and Serotonin</b>	385
Nitroprusside	307	Renin	385
Nitroglycerin	313	Plasma Kinins	388
Trimethaphan	316	Serotonin	389
Diazoxide	317	<b>23</b>	
Dipyridamole	318	<b>Hormones as Drugs</b>	394
Papaverine	318	Introduction	394
Purines	318	Anterior Pituitary Hormones	394
<b>17</b>		Thyroid Gland Hormones	395
<b>Cardiac Antidysrhythmic Drugs</b>	322	Drugs that Inhibit Thyroid Hormone Synthesis	395
Introduction	322	Ovarian Hormones	397
Classification	322	Androgens	399
<b>18</b>		Corticosteroids	400
<b>Calcium Entry Blockers</b>	335		
Introduction	335		
Mechanism of Action	335		



**x Contents**

Posterior Pituitary Hormones	409
Chymopapain	413
<b>24</b>	
<b>Insulin and Oral Hypoglycemics</b>	<b>415</b>
Introduction	415
Insulin	415
Oral Hypoglycemics	419
<b>25</b>	
<b>Diuretics</b>	<b>423</b>
Introduction	423
Thiazide Diuretics	423
Loop Diuretics	426
Osmotic Diuretics	428
Potassium-Sparing Diuretics	430
Aldosterone Antagonists	430
Carbonic Anhydrase Inhibitors	431
<b>26</b>	
<b>Gastric Antacids, Stimulants, and Antiemetics</b>	<b>433</b>
Gastric Antacids	433
Gastric Stimulants	437
Antiemetics	439
<b>27</b>	
<b>Anticoagulants</b>	<b>444</b>
Introduction	444
Heparin	444
Oral Anticoagulants	449
Antithrombotic Drugs	451
Thrombolytic Drugs	452
<b>28</b>	
<b>Antibiotics</b>	<b>454</b>
Introduction	454
Prophylactic Antibiotics	454
Penicillins	454
Penicillinase-Resistant Penicillins	456
Broad-Spectrum Penicillins	457
Allergy to Penicillins	457
Cephalosporins	458
Aminoglycosides	460
Tetracyclines	463
Chloramphenicol	465
Erythromycin	466
Clindamycin	467
Polymyxin and Colistin	467
Vancomycin	467
Bacitracin	468
Sulfonamides	468
Urinary Tract Antiseptics	471
Drugs for Treatment of Tuberculosis	472
Antifungal Drugs	474
Antiviral Drugs	475
<b>29</b>	
<b>Chemotherapeutic Drugs</b>	<b>480</b>
Introduction	480
Classification	480
Alkylating Drugs	481
Antimetabolites	486
Vinca Alkaloids	489
Antibiotics	490
Enzymes	493
Synthetics	494
Hormones	495
<b>30</b>	
<b>Antiepileptic Drugs</b>	<b>499</b>
Introduction	499
Mechanism of Seizure Activity	499
Mechanism of Drug Action	499
Plasma Concentrations	500
Hydantoins	500
Barbiturates	502
Primidone	503
Carbamazepine	503
Succinimides	504
Valproic Acid	505
Oxazolidinediones	505
Benzodiazepines	506
Acetazolamide	506
<b>31</b>	
<b>Drugs Used for Treatment of Parkinson's Disease</b>	<b>508</b>
Introduction	508
Levodopa	508
Carbidopa	511
Amantadine	511
Bromocriptine	511
Deprenyl	512
Anticholinergic Drugs	512
<b>32</b>	
<b>Drugs Used to Treat Hyperlipoproteinemia</b>	<b>514</b>
Introduction	514
Drugs That Affect Plasma Concentrations of Lipoproteins	514



Nicotinic Acid 515  
 Clofibrate 515  
 Gemfibrozil 516  
 Cholestyramine 516  
 Colestipol 516  
 Probucol 516  
 Dextrothyroxine 517

33

### **Central Nervous System Stimulants and Muscle Relaxants 518**

Central Nervous System Stimulants 518  
 Centrally Acting Muscle Relaxants 520

34

### **Vitamins 524**

Introduction 524  
 Water-Soluble Vitamins 524  
 Fat-Soluble Vitamins 530

35

### **Minerals 536**

Introduction 536  
 Calcium 536  
 Phosphate 541  
 Magnesium 541  
 Iron 542  
 Copper 544  
 Zinc 544  
 Chromium 544  
 Selenium 544  
 Manganese 544  
 Molybdenum 545

36

### **Blood Components and Substitutes 546**

Introduction 546  
 Blood Components 546  
 Topical Hemostatics 551  
 Blood Substitutes 552

37

### **Hyperalimentation Solutions 555**

Introduction 555  
 Enteral Nutrition 555  
 Parenteral Nutrition 556

38

### **Antiseptics and Disinfectants 561**

Introduction 561  
 Alcohols 561

Quaternary Ammonium Compounds 561  
 Chlorhexidine 562  
 Iodine 562  
 Hexachlorophene 563  
 Formaldehyde 563  
 Glutaraldehyde 563  
 Cresol 563  
 Silver Nitrate 563  
 Mercury 563  
 Ethylene Oxide 564

## **SECTION II**

## **PHYSIOLOGY**

39

### **Cell Structure and Function 566**

Introduction 566  
 Fluid Environment of Cells 566  
 Anatomy of a Cell 566  
 Ingestion by Cells 570  
 Control of Cell Function 570  
 Cell Membrane Transport 571  
 Electrical Potentials Across Cell Membranes 574  
 Action Potentials 575

40

### **Body Fluids 577**

Introduction 577  
 Total Body Water 577  
 Blood Volume 578  
 Measurement of Compartmental Fluid Volumes 579  
 Constituents of Body Fluid Compartments 580  
 Osmosis 581  
 Changes in Volumes of Body Fluid Compartments 581

41

### **Central Nervous System 583**

Introduction 583  
 Cerebral Cortex 583  
 Cerebral Blood Flow 587  
 Cerebrospinal Fluid 588  
 Electroencephalogram 590  
 Evoked Potentials 592  
 Brain Stem 592  
 Spinal Cord 595  
 Anatomy of Nerve Fibers 597

Transmission of Neuronal Information	600	Determinants of Tissue Blood Flow	646
Neurotransmitters	603	Control of Tissue Blood Flow	648
Electrical Events During Neuronal		Regulation of Arterial Blood Pressure	653
Excitation	604	Regulation of Cardiac Output and Venous	
Motor Responses	605	Return	658
Vision	608	Fetal Circulation	661
Hearing	613		
Equilibrium	614	<b>45</b>	
Chemical Senses	614	<b>Capillaries and Lymph Vessels</b>	664
Body Temperature	616	Capillaries	664
Nausea and Vomiting	619	Lymph Vessels	668
		Edema	669
<b>42</b>			
<b>Autonomic Nervous System</b>	622	<b>46</b>	
Introduction	622	<b>Pulmonary Circulation</b>	671
Anatomy of the Sympathetic Nervous		Introduction	671
System	622	Anatomy	671
Anatomy of the Parasympathetic Nervous		Intravascular Pressures	672
System	624	Interstitial Fluid Space	673
Physiology of the Autonomic Nervous		Pulmonary Blood Volume	673
System	625	Pulmonary Blood Flow and	
Interactions of Neurotransmitters with		Distribution	674
Receptors	628	Pulmonary Edema	676
Effects of Autonomic Nervous System		Events That Obstruct Pulmonary Blood	
Innervation	630	Flow	676
Residual Autonomic Nervous System			
Tone	630	<b>47</b>	
Adrenal Medulla	631	<b>Heart</b>	678
		Cardiac Physiology	678
<b>43</b>		Coronary Blood Flow	683
<b>Pain</b>	633	Dynamics of Heart Sounds	685
Introduction	633	Conduction of the Cardiac Impulse	687
Types of Pain	633	Circulatory Effects of Heart Disease	689
Pain Receptors	633	Myocardial Infarction	691
Transmission of Pain Signals	634	Angina Pectoris	693
Reaction to Pain	636	Cardiac Failure	693
Referred Pain	636	Circulatory Shock	695
Visceral Pain	637		
Parietal Pain	637	<b>48</b>	
Embryologic Origin and Localization of		<b>The Electrocardiogram and Analysis of Cardiac</b>	
Pain	637	<b>Dysrhythmias</b>	699
		Electrocardiogram	699
<b>44</b>		Cardiac Dysrhythmias	703
<b>Systemic Circulation</b>	639		
Introduction	639	<b>49</b>	
Components of the Systemic		<b>Lungs</b>	709
Circulation	639	Anatomy of the Lungs	709
Physical Characteristics of the Systemic		Pulmonary Ventilation	709
Circulation	640	Pulmonary Surfactant	710
Physical Characteristics of Blood	645	Compliance	711

Lung Volumes and Capacities	711	Regulation of the Characteristics of Body Fluids	770
Minute Ventilation	713	Acute Renal Failure	776
Control of Ventilation	714	Chronic Renal Failure	776
Respiratory Passageways	718	Nephrotic Syndrome	777
Nonventilatory Functions of the Lungs	719	Transport of Urine to the Bladder	778
<b>50</b>		<b>54</b>	
<b>Pulmonary Gas Exchange and Blood Transport of Gases</b>	<b>721</b>	<b>Liver and Gastrointestinal Tract</b>	<b>780</b>
Pulmonary Gas Exchange	721	Liver	780
Blood Transport of Oxygen and Carbon Dioxide	725	Gastrointestinal Tract	784
Changes Associated with High Altitude	731	<b>55</b>	
Changes Associated with Excessive Barometric Pressure	732	<b>Skeletal and Smooth Muscle</b>	<b>797</b>
<b>51</b>		Skeletal Muscle	797
<b>Acid–Base Balance</b>	<b>734</b>	Smooth Muscle	800
Introduction	734	<b>56</b>	
Mechanisms for Regulation of Hydrogen Ion Concentration	734	<b>Erythrocytes and Leukocytes</b>	<b>803</b>
Acid–Base Disturbances	739	Erythrocytes	803
<b>52</b>		Blood Groups	805
<b>Endocrine System</b>	<b>741</b>	Tissue Typing	806
Introduction	741	Leukocytes	807
Mechanisms of Action of Hormones	741	Inflammation	809
Pituitary Gland	741	Leukocytosis Due to Noninflammatory Causes	809
Adrenal Cortex	747	Agranulocytosis	810
Thyroid Gland	750	Immunity	810
Parathyroid Glands	752	<b>57</b>	
Pancreas	753	<b>Hemostasis and Blood Coagulation</b>	<b>814</b>
Male Sex Hormones	757	Hemostasis	814
Female Sex Hormones	758	Blood Coagulation	815
<b>53</b>		<b>58</b>	
<b>Kidneys</b>	<b>761</b>	<b>Metabolism of Nutrients</b>	<b>819</b>
Introduction	761	Introduction	819
Nephron	761	Metabolism of Carbohydrates	819
Renal Blood Flow	762	Metabolism of Lipids	821
Glomerular Filtrate	764	Metabolism of Proteins	824
Renal Tubular Function	766	<b>Drug Index</b>	<b>827</b>
Tubular Transport Maximum	770	<b>General Index</b>	<b>831</b>

---

S E C T I O N I

# PHARMACOLOGY

---

---

# C H A P T E R 1

## Pharmacokinetics and Pharmacodynamics of Injected and Inhaled Drugs

---

### INTRODUCTION

Pharmacokinetics is the quantitative study of the absorption, distribution, metabolism, and excretion of injected or inhaled drugs and their metabolites (*i.e.*, what the body does to a drug) (Hug, 1978; Stanski and Watkins, 1982). Coupled with the dose of drug administered, pharmacokinetics determines the concentration of drug at its sites of action (*i.e.*, receptors) and, thus, the intensity of the drug's effects with time. Pharmacokinetics also determines variations in plasma concentrations of a drug among patients resulting from differences in its absorption, distribution, and elimination. Selection and adjustment of drug dosage schedules and interpretation of measured plasma concentrations of drugs are facilitated by an understanding of pharmacokinetic principles.

Pharmacodynamics is the study of the intrinsic sensitivity or responsiveness of receptors to a drug and the mechanisms by which these effects occur (*i.e.*, what the drug does in the body) (Hull, 1979; Maze, 1981; Stanski and Watkins, 1982). Structure activity relationships relate the actions of drugs to their chemical structure and facilitate design of drugs with more desirable pharmacologic properties. Intrinsic sensitivity of receptors is determined by measuring plasma concentrations of a drug required to evoke specific pharmacologic responses (Kauffman, 1981). Variability exists in the intrinsic sensitivity of receptors among patients. As a result, at similar plasma concentrations of drug, some patients show a thera-

peutic response, others show no response, and, in others, toxicity develops.

### DESCRIPTION OF DRUG RESPONSE

*Hyperreactive* is the term used for people in whom an unusually low dose of drug produces its expected pharmacologic effects. *Hypersensitive* is the term usually reserved for people who are allergic to a drug. *Hyporeactive* describes people who require unusually large doses of drug to evoke expected pharmacologic effects. Hyporeactivity acquired from chronic exposure to a drug is better termed *tolerance*. Cross-tolerance frequently develops between drugs of different classes that produce similar pharmacologic effects (*e.g.*, alcohol and inhaled anesthetics). Tolerance that develops acutely with only a few doses of a drug, such as thiopental, is termed *tachyphylaxis*. The most important factor in the development of tolerance to drugs such as the opioids, barbiturates, and alcohol is neuronal adaptation referred to as cellular tolerance. Other mechanisms of tolerance may include enzyme induction and depletion of neurotransmitters by virtue of sustained stimulation. Immunity is present when hyporeactivity is due to formation of antibodies. Idiosyncrasy is present when an unusual effect of a drug occurs in a small percentage of patients regardless of the dose of drug. More appropriately, unusual effects of drugs should be described precisely in terms of their documented or likely mechanisms (*e.g.*, allergy, genetic difference).

An *additive effect* means that a second drug acting with the first drug will produce an effect equal to an algebraic summation. For example, the anesthetic effects of two different inhaled anesthetics are additive as reflected by MAC equivalents (Quasha *et al*, 1980) (see the section entitled Minimum Alveolar Concentration). Synergistic means two drugs interact to produce an effect that is greater than algebraic summation. Antagonism is when two drugs interact to produce an effect less than algebraic summation.

A drug that activates a receptor by binding to the receptor is called an *agonist*. An *antagonist* is a drug that binds to the receptor without activating the receptor and at the same time prevents an agonist from stimulating the receptor. Competitive antagonism is present when increasing concentrations of the antagonist progressively inhibit the response to an unchanging concentration of agonist. Noncompetitive antagonism is present when, after administration of an antagonist, even high concentrations of agonist cannot completely overcome the antagonism.


Termination of drug effect is by metabolism, excretion, or redistribution. Redistribution is a factor in terminating drug effect primarily when a highly lipid-soluble drug is administered rapidly intravenously.

## PHARMACOKINETICS OF INJECTED DRUGS

### Compartmental Models

Pharmacokinetics of injected drugs has been simplified by considering the body to be comprised of a number of compartments representing theoretical spaces. This approach permits a mathematical modeling of the disposition of a drug within the body based on its pharmacokinetics. In this regard, it is essential that the analytical procedures used in pharmacokinetic studies measure the parent drug and its metabolites separately.

A two-compartment model can be used to illustrate basic concepts of pharmacokinetics that also apply to more complex models (Fig. 1-1) (Stanski and Watkins, 1982). In the two-compartment model, drug is introduced by intravenous injection directly into the central compartment. Drug subsequently distributes to a peripheral compartment only to return eventually to the central compartment where clearance from the body occurs.



**FIGURE 1-1.** A two-compartment pharmacokinetic model as derived from a biexponential plasma decay curve (see Fig. 1-2).  $k_{12}$  and  $k_{21}$  are the rate constants that characterize intercompartmental transfer of drugs, and  $k_e$  is the rate constant for overall drug elimination from the body. (From Stanski DR, Watkins WD. Drug Disposition in Anesthesia. New York, Grune and Stratton, 1982. Reproduced by permission of the authors and publisher.)

The central compartment includes intravascular fluid and highly perfused tissues (*e.g.*, heart, brain, lungs, liver, kidneys) into which uptake of drug is rapid (see the section entitled Distribution). In an adult, these tissues represent about 10% of body mass but receive almost 75% of the cardiac output. This central compartment is defined only in terms of its apparent volume, which is calculated and does not necessarily correspond to actual anatomic volumes (see the section entitled Volume of Distribution). Likewise, the peripheral compartment is defined in terms of its apparent volume. A large calculated volume for the peripheral compartment suggests extensive uptake of drug by those tissues that constitute the peripheral compartment. Any residual drug present in the peripheral compartment at the time of repeat injection will diminish the effect of distributive processes on the reduction of the plasma concentration and lead to exaggerated effects of the repeat dose (*i.e.*, cumulative drug effect). The degree of cumulative drug effect can be calculated knowing the drug's volume of distribution, elimination half-time, and dosing interval.


Despite the usefulness of compartmental models to depict the pharmacokinetics of drugs, it must be appreciated that these pharmacokinetic characteristics are most often derived from healthy and ambulatory adults with a low fat-to-lean body ratio. Conversely, drugs are most likely to be administered to patients with chronic disease at various extremes of age, hydration, and nutrition.

## Plasma Concentration Curves

A graphic plot of the logarithm of the plasma concentration of drug versus time following a rapid (bolus) intravenous injection characterizes the distribution and elimination half-times of that drug (Fig. 1-2) (Stanski and Watkins, 1982). Logarithms provide a convenient means for managing the large range in the plasma concentrations encountered after an intravenous injection of drug. In addition, logarithms are appropriate for depiction of the first-order kinetics characteristic of the distribution and elimination of most drugs.

### Distribution and Elimination Phases

Two distinct phases (*i.e.*, biexponential) are present on the graphic plot of the decline in the plasma concentration of a drug (Fig. 1-2) (Stanski and Watkins, 1982). The first phase is designated the distribution (alpha) phase. This phase begins immediately after intravenous injection of the drug and reflects its distribution from the circulation to peripheral tissues. The second phase is designated the elimination (beta) phase. This phase is characterized by a gradual decline in the plasma concentration of the drug and reflects its



**FIGURE 1-2.** Schematic depiction of the decline in the plasma concentration of drug with time following rapid intravenous injection into the central compartment (see Fig. 1-1). Two distinct phases (*e.g.*, biexponential) characterize this curve, being designated the distribution and elimination phases. (From Stanski DR, Watkins WD. Drug Disposition in Anesthesia. New York, Grune and Stratton, 1982. Reproduced by permission of the authors and publisher.)

elimination from the central vascular compartment by renal and hepatic clearance mechanisms (see Fig. 1-1) (Stanski and Watkins, 1982).

**ELIMINATION HALF-TIME.** The rate of drug elimination can be characterized by the slope of the line representing the log plasma concentration of drug plotted against time during the elimination phase. The numerical value of the slope of the elimination phase is defined as the first-order rate constant. The concept of elimination half-time, however, is used more frequently than the rate constant. *Elimination half-time* is the time necessary for the plasma concentration of drug to decline 50% during the elimination phase. Conversely, *half-life* refers to the total amount of drug in the body and the time necessary for elimination of 50% of this total from the body. Half-time and half-life are not equal when the decline of drug concentrations in all tissues does not parallel the decline in the plasma concentration.

Elimination half-time of a first-order process can be estimated graphically by selecting any point on the straight line portion of the elimination phase and measuring the time interval to the point on the same line that represents one-half the original concentration (Fig. 1-2) (Stanski and Watkins, 1982). The elimination half-time can also be calculated as  $0.63$  divided by the elimination rate constant for that drug.

Elimination half-time of a drug is directly proportional to its volume of distribution and inversely proportional to its clearance. For this reason, renal or hepatic disease that alters volume of distribution and/or clearance will alter the elimination half-time.

The amount of drug remaining in the body is related to the number of elimination half-times that have elapsed. For example, if 50% of a drug is eliminated in 10 minutes, another 10 minutes will be required for elimination of one-half the remaining drug. About five elimination half-times are required for almost complete (96.9%) elimination of a drug (Table 1-1) (Hug, 1978). For this reason, drug accumulation is predictable if dosing intervals are less than this period of time. Drug accumulation continues until the rate of drug elimination equals the rate of drug administration. As with drug elimination, the time necessary for a drug to achieve a steady state plasma concentration ( $C_{pss}$ ) with intermittent dosing is about five elimination half-times.



**Table 1-1**  
*Relationship of Half-Times to Amount of Drug Eliminated*

Number of Half-Times	Fraction of Initial Amount Remaining	Percent of Initial Amount Eliminated
0	1	0
1	1/2	50
2	1/4	75
3	1/8	87.5
4	1/16	93.8
5	1/32	96.9
6	1/64	98.4

(Adapted from Hug CC. Pharmacokinetics of drugs administered intravenously. *Anesth Analg* 1978; 57:704–23 with permission of the author and publisher)

## Route of Administration and Systemic Absorption of Drugs

The choice of route of administration for a drug should be based on an appreciation of factors that influence the systemic absorption of drugs. The rate of systemic absorption of a drug determines its intensity and duration of action. Changes in the rate of systemic absorption may necessitate an adjustment in the dose or time interval between repeated drug doses (Azarnoff and Huffman, 1976).

Systemic absorption, regardless of the route of drug administration, is dependent on drug solubility. Local conditions at the site of absorption alter solubility, particularly in the gastrointestinal tract. Circulation to the site of absorption is also important in the rapidity of absorption. For example, increased blood flow by external massage or local application of heat enhances systemic absorption, whereas decreased blood flow due to vasoconstriction impedes drug absorption. Finally, the area of absorbing surface to which a drug is exposed is an important determinant of drug absorption.

### Oral Administration

Oral administration of a drug is the most convenient and economic route of administration. Disadvantages of the oral route of administration include (1) emesis because of irritation of the gastrointestinal mucosa by the drug, (2) destruction of the drug by digestive enzymes or low gas-


tric fluid pH, and (3) irregularities in absorption in the presence of food or other drugs. Furthermore, drugs may be metabolized by enzymes or bacteria in the gastrointestinal tract before systemic absorption can occur.

Following oral administration, the onset of drug effect is largely determined by the rate and extent of absorption from the gastrointestinal tract. The principal site of drug absorption after oral administration is from the small intestine, reflecting the large surface area of this portion of the gastrointestinal tract. Lipid solubility is necessary to facilitate drug absorption across epithelial cells lining the gastrointestinal tract. Changes in gastrointestinal pH that favor the lipid-soluble nonionized fraction of drug thus favor systemic absorption. Drugs, such as aspirin, which are weak acids, become more highly ionized in the alkaline environment of the small intestine, but absorption is still great because of the large surface area. Furthermore, absorption also occurs in the stomach, where gastric fluid pH is low.

**FIRST-PASS HEPATIC EFFECT.** Drugs absorbed from the gastrointestinal tract enter the portal venous blood and thus pass through the liver before entering the systemic circulation for delivery to tissue receptors (Fig. 1-3). This is known as the *first-pass hepatic effect*, and, for drugs that undergo extensive hepatic extraction and metabolism (*e.g.*, propranolol, lidocaine), this is the reason for large differences between effective oral and intravenous doses (Routledge and Shand, 1979).

### Sublingual Administration

The sublingual route of administration permits rapid onset of drug effect by virtue of bypassing



**FIGURE 1-3.** Drugs administered orally are absorbed from the gastrointestinal tract into the portal venous blood and pass through the liver (*e.g.*, first-pass hepatic effect) before entering the systemic circulation for distribution to receptors. Conversely, intravenously administered drugs gain rapid access to the systemic circulation without an initial impact of metabolism in the liver.

the liver and thus preventing the first-pass hepatic effect on the initial plasma concentration of drug. For example, venous drainage from the sublingual area is into the superior vena cava. Evidence of the value of bypassing the first-pass hepatic effect is the efficacy of sublingual nitroglycerin. Conversely, oral administration of nitroglycerin is ineffective because extensive first-pass hepatic metabolism prevents achievement of a therapeutic plasma concentration. Buccal administration is an alternative to sublingual placement of drug, being better tolerated and less likely to stimulate salivation. Salivation speeds solution of a tablet so that it is more easily swallowed and rendered less active (Bell *et al*, 1985).

Drugs administered rectally also bypass the liver and enter directly into the systemic circulation. Nevertheless, rectal absorption is often unpredictable, and irritation of the rectal mucosa may occur.

### **Transdermal Administration**

Transdermal administration of drugs provides sustained therapeutic plasma concentrations of the drug with a low total dosage that results in minimal associated drug-induced side effects (Shaw and Chandrasekaran, 1978; Shaw and Urquhart, 1980). This route of administration is devoid of the complexity of continuous intravenous infusion techniques, and the low incidence of side effects owing to the minimal total dose administered contributes to high patient compliance and acceptance. Characteristics of drugs that favor predictable transdermal absorption include (1) combined water and lipid solubility, (2) molecular weight less than 1000, and (3) *pH* 5 to 9 in a saturated aqueous solution. Scopolamine, clonidine, and nitroglycerin are examples of drugs that undergo predictable transdermal absorption (see Chapters 10, 15, and 16).

The rate-limiting step in transdermal absorption of drugs is diffusion across the stratum corneum of the epidermis. Significant differences in the thickness and chemistry of the stratum corneum are reflected in the skin's permeability. For example, skin may be 10 to 20  $\mu\text{m}$  thick on the back and abdomen compared with 400 to 600  $\mu\text{m}$  on the palmar surfaces on the hands. Likewise, skin permeation studies have shown substantial regional differences for systemic absorption of

scopolamine (Shaw and Chandrasekaran, 1978). The postauricular zone, because of its thin epidermal layer and somewhat higher temperature, is the only area that is sufficiently permeable for predictable and sustained absorption of scopolamine. Systemic absorption is least when scopolamine is applied to the thigh and intermediate when applied to the back or chest.

It is likely that transdermal absorption of drug initially occurs along sweat ducts and hair follicles (*i.e.*, diffusion shunts). Following saturation of skin binding sites with drug, diffusion through the stratum corneum becomes the dominant pathway for absorption. The stratum corneum sloughs and regenerates at a rate such that 7 days of adhesion appears to be the duration limit for one application of a transdermal system. There is no evidence for active transport of drugs across the skin.

### **Parenteral Administration**

Parenteral administration may be required to ensure absorption of the active form of the drug. Systemic absorption after parenteral injection is usually more rapid and more predictable than after oral administration. The effective administered dose can be more precisely determined when absorption is predictable. Parenteral administration is the only acceptable route of drug administration in an unconscious or otherwise uncooperative patient.

Systemic absorption from subcutaneous and intramuscular injection sites occurs by simple diffusion along the concentration gradient from the site of drug deposition to plasma. Rate of systemic absorption is limited by the area of the absorbing capillary membranes and by solubility of the drug in interstitial fluid. Large aqueous channels in vascular endothelium account for the unimpeded diffusion of drug molecules, regardless of their lipid solubility (see Chapter 39).

Intravenous administration avoids those factors that limit systemic absorption by other routes. As a result, the desired concentration of drug in the blood can be more rapidly and precisely achieved by this route of administration. Irritant drugs are more comfortably administered by this route because blood vessel walls are relatively insensitive and the injected drug is rapidly diluted in the blood.